## 3 Results
### Changes in Serum OVA-slg E Content  
Within the OVA control group, a statistically significant augmentation (\(p<0.01\)) in the content of serum OVA-slg E was evident when contrasted with the intact vehicle control group. In contrast, a significant and consistent decline (\(p<0.01\)) in the serum OVA-slg E content was distinctly observed across all three doses of the IAP-extract-administered groups, in accordance with a dose-dependent pattern. In particular, the IAP\({}_{400}\) group exhibited an inhibitory effect against the OVA-induced increase in the serum OVA-slg E content, which is a response that is comparable to that elicited by the DEXA-administered group (Figure 3).  
\begin{table}
\begin{tabular}{c c c c c c c} \hline \hline
**Groups** & **Total Cells** & \multicolumn{3}{c}{**Total Leukocytes**} & \multicolumn{3}{c}{**Differential Counts**} \\ \cline{3-6}  & & **Lymphocytes** & **Neutrophils** & **Eosinophils** & **Monocytes** \\ \hline Controls & & & & & & \\ \multicolumn{1}{c}{Intact vehicle} & 15.00 \(\pm\) 1.94 & 10.60 \(\pm\) 2.01 & 6.90 \(\pm\) 1.60 & 2.20 \(\pm\) 0.79 & 0.21 \(\pm\) 0.19 & 0.21 \(\pm\) 0.13 \\ \multicolumn{1}{c}{OVA} & 57.80 \(\pm\) 3.55\({}^{\text{a}}\) & 51.50 \(\pm\) 3.47\({}^{\text{c}}\) & 32.00 \(\pm\) 3.74\({}^{\text{a}}\) & 11.40 \(\pm\) 1.26\({}^{\text{c}}\) & 2.99 \(\pm\) 0.80\({}^{\text{c}}\) & 3.12 \(\pm\) 0.79\({}^{\text{c}}\) \\ \multicolumn{1}{c}{Reference} & & & & & & \\ \multicolumn{1}{c}{DEXA} & 25.30 \(\pm\) 4.14\({}^{\text{ab}}\) & 20.10 \(\pm\) 2.73\({}^{\text{ee}}\) & 12.10 \(\pm\) 1.52\({}^{\text{ab}}\) & 4.80 \(\pm\) 2.10\({}^{\text{de}}\) & 0.81 \(\pm\) 0.27\({}^{\text{ee}}\) & 0.87 \(\pm\) 0.19\({}^{\text{ee}}\) \\ \multicolumn{1}{c}{Test material groups} & & & & & & \\ \multicolumn{1}{c}{IAP\({}_{400}\)} & 25.60 \(\pm\) 3.50\({}^{\text{ab}}\) & 20.60 \(\pm\) 3.60\({}^{\text{ee}}\) & 12.30 \(\pm\) 1.64\({}^{\text{ab}}\) & 4.90 \(\pm\) 1.66\({}^{\text{ee}}\) & 0.84 \(\pm\) 0.32\({}^{\text{ee}}\) & 0.89 \(\pm\) 0.31\({}^{\text{ee}}\) \\ \multicolumn{1}{c}{IAP\({}_{200}\)} & 33.40 \(\pm\) 5.27\({}^{\text{ab}}\) & 27.00 \(\pm\) 4.71\({}^{\text{ee}}\) & 16.50 \(\pm\) 3.03\({}^{\text{ab}}\) & 6.20 \(\pm\) 1.55\({}^{\text{ee}}\) & 1.33 \(\pm\) 0.33\({}^{\text{ee}}\) & 1.69 \(\pm\) 0.40\({}^{\text{ee}}\) \\ \multicolumn{1}{c}{IAP\({}_{100}\)} & 42.30 \(\pm\) 4.24\({}^{\text{ab}}\) & 34.80 \(\pm\) 2.49\({}^{\text{ee}}\) & 21.40 \(\pm\) 2.46\({}^{\text{ab}}\) & 7.60 \(\pm\) 1.17\({}^{\text{ee}}\) & 1.64 \(\pm\) 0.22\({}^{\text{ee}}\) & 2.12 \(\pm\) 0.21\({}^{\text{cf}}\) \\ \hline \hline \end{tabular}  
* Cell number: 1 \(\times\) 10\({}^{4}\) cells/mL. \({}^{\text{a}}\)\(p<0.01\) compared with intact vehicle control using THSD test; \({}^{\text{b}}\)\(p<0.01\) compared with OVA control using THSD test; \({}^{\text{c}}\)\(p<0.01\) and \({}^{\text{d}}\)\(p<0.05\) compared with intact vehicle control using DT3 test; \({}^{\text{e}}\)\(p<0.01\) and \({}^{\text{f}}\)\(p<0.05\) compared with OVA control using DT3 test.  
\end{table}
Table 1: Cytology of BALF in intact or OVA-induced allergic asthma mice.  
Figure 3: Serum OVA-slg E levels in intact or OVA-induced allergic asthma mice. \({}^{\text{a}}\)\(p<0.01\) compared with intact vehicle control using DT3 test; \({}^{\text{b}}\)\(p<0.01\) compared with OVA control using DT3 test.